Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Compare rebalancing frequency between index funds and target-date funds and what that means for risk, fees, and long-term performance. A quick look at when to expect adjustments.
28,361 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Netflix just posted a record quarterly revenue, but the forecast for the next quarter came in softer than expected. H...
Retirees are timing Roth conversions to stay in favorable tax brackets, aiming to slash lifetime taxes and reduce req...
Bitcoin slid toward the $58,000 level as Strategy's STRC dropped to fresh lows and MSTR followed lower. This article ...
NexaTech Holdings, a $40 billion market-cap company, raised its revenue guidance on stronger-than-expected demand, si...
Beaten-down brands aren’t a bet on luck—they’re a test of resilience. This piece explores two stocks down right hold ...
When Paramount beat Netflix in the bid for Warner Bros. Discovery’s assets, headlines screamed victory. This piece di...
In Buffett's final chapters as Berkshire's CEO, one move stood out: selling a stock that helped build his fortune. Th...
When a Cheesecake Factory executive moved nearly 4,800 shares, it stirred questions about CAKE stock. This guide brea...
Early market shocks during retirement can permanently damage a portfolio. Experts say the first years retirement most...
Cerebras stock is climbing as fresh news and growing AI demand spark investor excitement. This guide breaks down the ...
A sharp intraday drop in Micron shares sparked by AI memory demand concerns set off a broader discussion about pricin...